ELVN
Enliven Therapeutics Inc.
NASDAQ: ELVN · HEALTHCARE · BIOTECHNOLOGY
$41.23
-2.76% today
Updated 2026-04-30
Market cap
$2.58B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$15 – $49
Volume
1.2M
Enliven Therapeutics Inc. (ELVN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-27.00%
ROA
-18.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | — | — | — | — | — |
| 2018 | — | $-11.34M | — | — | — |
| 2019 | — | $-23.46M | — | — | — |
| 2020 | $0.00 | $-18.97M | — | — | — |
| 2021 | $0.00 | $-24.74M | — | — | — |
| 2022 | $0.00 | $-37.66M | — | — | — |
| 2023 | $0.00 | $-71.58M | — | — | — |
| 2024 | $0.00 | $-89.02M | — | — | — |
| 2025 | $0.00 | $-103.69M | — | — | — |